Viemed Healthcare (VMD) Q3 FY2026 earnings: revenue $81 million, up 12.2% on the year

Viemed Healthcare, Inc. (VMD) reported revenue of $81 million for Q3 FY2026, the quarter ended 30 September 2026, up 12.2% on the same quarter a year earlier. Net income was $5 million, up 32.0% on the year, and diluted earnings per share $0.11. The figures are the company's own, from the 10-Q it filed with the SEC on 4 November 2026.

Revenue

$81 million

+12.2% on the year · +3.3% on the quarter

Q4 FY2024Q3 FY2026

Operating margin

8.6%

7.8% a year earlier

Q4 FY2024Q3 FY2026

Net income

$5 million

+32.0% on the year · +67.8% on the quarter

Q4 FY2024Q3 FY2026

Diluted EPS

$0.11

+22.2% on the year · +57.1% on the quarter

Q4 FY2024Q3 FY2026

this quarterthe same quarter a year earlierHover a bar for its figure.

What management said

Guidance figures: 1 lowered, 2 narrowed.

Record quarterly revenue of $80.7M: Net revenue reached a Company record, up $8.8 million or 12.2% from the prior-year quarter and 3.3% sequentially, with management calling it another record quarter.
Adjusted EBITDA margin rose to 21.1%: Adjusted EBITDA was $17.1 million, up 5.8% year over year and 24.4% sequentially. The company said the margin improved about 350 basis points from 17.6% in the second quarter.
PAP therapy patients rose 37.5%: PAP therapy patients reached 43,861 during the third quarter, after 37,825 at June 30, 2026, according to the second-quarter release.

Read the earnings call summary

Income statement (profit and loss)

$ million	Q3 FY2026	Q2 FY2026	Q3 FY2025	On the quarter	On the year
Revenue	80.7	78.1	71.9	+3.3%	+12.2%
Cost of revenue	34.5	33.0	30.6	+4.3%	+12.8%
Gross profit	46.2	45.0	41.3	+2.5%	+11.7%
Gross margin	57.3%	57.7%	57.5%
Research and development	0.5	0.5	0.8	-0.6%	-35.4%
Selling, general and administrative	35.5	37.1	31.9	-4.4%	+11.2%
Operating income	7.0	4.5	5.6	+56.1%	+23.4%
Operating margin	8.6%	5.7%	7.8%
Interest expense	0.2	0.2	0.5	-28.6%	-65.1%
Pre-tax income	6.8	4.1	5.1	+67.5%	+32.1%
Income tax	2.0	1.2	1.5	+77.9%	+33.4%
Effective tax rate	30.2%	28.4%	29.9%
Net income	4.6	2.8	3.5	+67.8%	+32.0%
Net margin	5.7%	3.5%	4.9%
Diluted EPS	$0.11	$0.07	$0.09	+57.1%	+22.2%

$ million except per share.

Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.

Cash flow

$ million	Q3 FY2026	Q2 FY2026	Q3 FY2025	On the quarter	On the year
Operating cash flow	11.5	15.9	18.4	-27.8%	-37.5%
Capital expenditure	8.6	8.5	7.6	+1.8%	+12.8%
Free cash flow	2.9	7.4	10.7	-61.4%	-73.2%
Free cash flow margin	3.6%	9.5%	14.9%
Cash from investing	-7.5	-7.8	-32.3
Cash from financing	-5.0	-7.1	5.0
Depreciation and amortisation	0.4	0.4	0.4	+1.0%	-1.3%
Share-based compensation	2.5	2.0	2.2	+21.9%	+13.6%
Buybacks	1.0	5.3	11.6	-81.6%	-91.5%
Diluted shares, weighted	41m	41m	40m	+0.2%	+1.7%
Shares outstanding at period end	38m	38m	38m	-0.1%	+0.1%

Cash flow lines for the quarter; where the company files them year to date, the quarter is the difference between two filings.

Balance sheet

$ million	Q3 FY2026	Q2 FY2026	Q3 FY2025	On the quarter	On the year
Shareholders' equity	150	144	134	+4.2%	+12.3%
Non-controlling interest	1.9	1.9	1.9	-1.9%	+0.6%
Debt	5.0	7.1	21.1	-29.2%	-76.2%
Operating lease liabilities	2.8	3.1	2.4	-8.3%	+17.6%
Other liabilities	47.8	48.1	43.3	-0.6%	+10.3%
Total liabilities and equity	208	204	202	+1.7%	+2.6%
Fixed assets	75.6	77.2	80.5	-2.0%	-6.1%
Goodwill	58.9	58.9	58.5	0.0%	+0.8%
Intangible assets	1.1	1.2	1.3	-5.4%	-18.8%
Cash and equivalents	9.7	10.7	11.1	-9.4%	-13.0%
Receivables	34.9	32.2	27.4	+8.2%	+27.3%
Inventory	4.6	5.3	5.3	-13.6%	-13.6%
Other assets	22.9	18.8	18.2	+21.8%	+25.6%
Total assets	208	204	202	+1.7%	+2.6%

Questions

What was Viemed Healthcare's revenue in Q3 FY2026?

Viemed Healthcare (VMD) reported revenue of $81 million for Q3 FY2026, the quarter ended 30 September 2026, up 12.2% on the same quarter a year earlier.

How much did Viemed Healthcare earn in Q3 FY2026?

Net income for Q3 FY2026 was $5 million, up 32.0% on the year, and diluted earnings per share $0.11.

When did Viemed Healthcare report Q3 FY2026 results?

Viemed Healthcare filed its 10-Q for the quarter ended 30 September 2026 with the SEC on 4 November 2026.

Quarterly results, the last 20 quarters

	Q4 FY2021 *	Q1 FY2022	Q2 FY2022	Q3 FY2022	Q4 FY2022 *	Q1 FY2023	Q2 FY2023	Q3 FY2023	Q4 FY2023 *	Q1 FY2024	Q2 FY2024	Q3 FY2024	Q4 FY2024 *	Q1 FY2025	Q2 FY2025	Q3 FY2025	Q4 FY2025 *	Q1 FY2026	Q2 FY2026	Q3 FY2026
Revenue	32.0	32.3	33.3	35.8	37.5	39.6	43.3	49.4	50.7	50.6	55.0	58.0	60.7	59.1	63.1	71.9	76.2	75.4	78.1	80.7
Cost of revenue	12.3	12.5	12.9	14.1	14.6	15.6	17.2	18.8	18.6	20.8	22.1	23.6	24.6	25.9	26.3	30.6	32.1	32.6	33.0	34.5
Gross profit	19.7	19.7	20.4	21.7	22.9	24.0	26.1	30.6	32.1	29.8	32.9	34.4	36.1	33.3	36.7	41.3	44.1	42.8	45.0	46.2
Gross margin	62%	61%	61%	61%	61%	61%	60%	62%	63%	59%	60%	59%	60%	56%	58%	57%	58%	57%	58%	57%
R&D	0.6	0.6	0.7	0.7	0.7	0.8	0.8	0.6	0.7	0.8	0.8	0.8	0.8	0.8	0.8	0.8	0.6	0.6	0.5	0.5
SG&A	14.2	15.8	17.5	17.7	17.2	19.8	20.6	23.7	23.9	24.8	26.5	26.7	28.2	28.4	28.8	31.9	32.2	34.8	37.1	35.5
Operating income	4.7	2.2	1.0	1.5	3.5	1.9	2.9	4.2	5.3	2.2	3.6	5.6	6.5	3.8	5.1	5.6	8.4	4.3	4.5	7.0
Operating margin	15%	7%	3%	4%	9%	5%	7%	9%	10%	4%	7%	10%	11%	6%	8%	8%	11%	6%	6%	9%
Interest expense	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	0.2	0.1	0.5	n/a	0.3	0.2	0.2
Pre-tax income	5.1	2.5	1.4	1.5	3.6	2.0	3.1	4.2	5.1	2.1	2.2	5.5	6.3	3.7	5.0	5.1	8.0	4.0	4.1	6.8
Tax rate	19%	30%	30%	30%	32%	25%	24%	31%	32%	24%	34%	29%	30%	26%	35%	30%	27%	32%	28%	30%
Net income	4.1	1.8	1.0	1.1	2.4	1.5	2.3	2.9	3.5	1.6	1.5	3.9	4.3	2.6	3.2	3.5	5.6	2.6	2.8	4.6
Net margin	13%	5%	3%	3%	6%	4%	5%	6%	7%	3%	3%	7%	7%	4%	5%	5%	7%	3%	4%	6%
Diluted EPS	$0.10	$0.04	$0.02	$0.03	$0.06	$0.04	$0.06	$0.07	$0.09	$0.04	$0.04	$0.10	$0.10	$0.06	$0.08	$0.09	$0.14	$0.06	$0.07	$0.11
Operating cash flow	8.7	7.1	4.9	8.0	7.7	10.5	7.6	13.8	13.3	1.2	10.2	12.7	15.0	2.9	12.3	18.4	18.4	8.1	15.9	11.5
Capital expenditure	6.7	4.0	7.0	6.3	5.6	4.7	6.1	7.4	7.9	6.0	8.9	11.0	11.8	15.5	8.1	7.6	8.7	6.7	8.5	8.6
Free cash flow	2.0	3.2	-2.1	1.6	2.1	5.8	1.5	6.4	5.4	-4.8	1.2	1.7	3.2	-12.6	4.1	10.7	9.7	1.4	7.4	2.9
Buybacks	0.0	1.9	5.1	1.9	n/a	0.0	0.0	0.0	0.0	n/a	n/a	0.0	n/a	0.0	1.7	11.6	0.0	1.4	5.3	1.0
Shares outstanding	40m	39m	38m	38m	38m	38m	38m	38m	39m	39m	39m	39m	39m	40m	40m	38m	38m	39m	38m	38m
Filing	10-K	10-Q	10-Q	10-Q	10-K	10-Q	10-Q	10-Q	10-K	10-Q	10-Q	10-Q	10-K	10-Q	10-Q	10-Q	10-K	10-Q	10-Q	10-Q

Each quarter as filed, linked to its filing.

* The fourth quarter is the full year less the first three quarters, because the company files the year and not the quarter on its own. A fourth quarter's EPS, and its diluted share count where shown, are from the company's results press release for that quarter, checked against the company's filed figures or a second data source. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and the share count are as they are. Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Cash flow lines filed year to date are the difference between two filings. Shares outstanding are at the period end where the balance sheet tags them, otherwise the count on the filing's cover page. A derived fourth-quarter EPS is left blank when a split in the year makes the arithmetic meaningless.

10-Q for the period ended 30 September 2026, filed 4 November 2026: the filing.